Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand to Report First Quarter 2017 Results on May 9th

Read More

Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone

Read More

Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology

Read More

Recent Events

Upcoming Events

Stock Snapshot

LGND
NASDAQ
Volume
Market Cap
Day Range
52-Week Range